AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 152 min read$ATNM

Some prostate cancers progress after targeted therapy. Actinium is testing radiation aimed at a different target.

Actinium Pharmaceuticals presented early Phase 1 trial data for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). The study aims to assess safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, with plans to advance to Actinium-225-labeled therapy. According to the company, ATNM-400 targets a novel antigen and could benefit a broad mCRPC patient population, including those resistant to PSMA-directed therapies.

Original reporting
stocktitan.net
Published Oct 15, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ATNM
Bullish
high confidence
Mentioned
$ATNM
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ATNMBullishMed
01

Why it matters

The disclosed Phase 1 data provide the first human safety and dosimetry readout, a key catalyst for valuation.

02

Market read

Early trial data for a novel oncology radiopharmaceutical can move the stock and influence sector sentiment.

03

What to watch

Regulatory timeline, manufacturing scale‑up, and competition from PSMA‑targeted agents could limit upside

Relevance 8/10Novelty 8/10Timing: ahead of the Oct 19 presentation

Background

Actinium Pharmaceuticals focuses on targeted radiotherapies; ATNM-400 is its lead non‑PSMA candidate.

Company-level read

Ticker impact

$ATNMBullishHigh confidence
Context

Actinium disclosed early Phase 1 data for ATNM-400, a non‑PSMA targeted alpha therapy for metastatic castration‑resistant prostate cancer.

Expected impact

likely upward pressure as investors price in the therapeutic potential and future trial milestones

Evidence & confidence

Early clinical data are material for a biotech; positive safety signals often lift share price ahead of further trial readouts.

Market effects

Sector

strengthens the non‑PSMA radiotherapy niche and may boost related biotech peers

Regional

U.S. biotech sector could see modest gains

Global

limited to oncology radiopharma investors

Counterpoint

What could challenge this read

Phase 1 data are early; safety signals may not translate to efficacy, so caution is warranted

Key entities

  • company
    Actinium Pharmaceuticals, Inc.

    Developer of ATNM-400 radiotherapy

Read at source← All news

StoryActinium presents first‑in‑human Phase 1 data for non‑PSMA radiotherapy ATNM‑400 in prostate cancer

Also covered by

1 outlet

Related articles

OCT 15
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals (ATNM) announced early Phase 1 trial results for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC), to be presented at EANM 2026. The study assesses safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, aiming to inform therapeutic dosing with Actinium-225-labeled ATNM-400.

prnewswire.com2 min
AUG 14
$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

prnewswire.com4 min
MAY 29
$ATNMLow

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

prnewswire.com3 min
MAY 29
$ATNMMedAI 9/10

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

prnewswire.com4 min
OCT 15
$NFLXMed

Bela Bajaria Is Out at Netflix, Peter Rice Is In

Netflix announced Bela Bajaria is stepping down as Chief Content Officer, replaced by Peter Rice. Ted Sarandos praised her decade of service. This follows Netflix's recent layoffs of 1,000 employees. Bajaria led content expansion, including unscripted programming and live events.

vulture.com2 min